Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 119 posts
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy
A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.
August 27, 2020 | Podcasts
August 25, 2020 | Blogs
COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.
August 25, 2020 | Infographics
CBPartners lists the top 10 long-term trends and implications of COVID-19 on the biopharma industry as biopharma leaders prepare for a post-COVID-19 world.
August 5, 2020 | Blogs
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.